Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with
major depressive disorder (MDD).
Secondary objective:
- To determine plasma concentrations of SR58878 (the active metabolite of SR58611A), for
pharmacokinetic population analyses, to evaluate the quality of life (QoL) in patients with
MDD, and to evaluate the efficacy of amibegron in patients with MDD.